Gonadotropin-releasing hormone antagonist: How good is the new hope?

Current Opinion in Obstetrics and Gynecology

Volumn 13, Issue 3, 2001, Pages 257-262

  Albano, Carola ^a   Platteau, Peter ^a   Devroey, Paul ^a  

^a CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; GANIRELIX; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE;

BREAST CARCINOMA; CANCER CELL; CELL PROLIFERATION; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIOSIS; ENDOMETRIUM CARCINOMA; FERTILIZATION IN VITRO; GONADORELIN RELEASE; HORMONE DEPENDENCE; HORMONE INHIBITION; HUMAN; PREGNANCY RATE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; TUMOR VOLUME; UTERUS MYOMA;

FEMALE; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HUMANS; INFERTILITY, FEMALE; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, GONADOTROPIN;

EID: 0034925636     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200106000-00002     Document Type: Review

References (54)

1. Hypothalamic FSH and LH-regulating hormone: Structure, physiology and clinical studies
2. Novel antagonists of GnRH: A compendium of their physiochemical properties, activities, relative potencies and efficacy in humans
3. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (Nafarelin)
4. Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in-vitro fertilization and their consequences for embryo development
5. Agonist-induced regulation of pituitary receptors for gonadotropin-releasing hormone: Dissociation of receptor recruitment from hormone release in cultured gonadotrops
6. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: An overview
7. Reproductive-endocrine and anaphylactoid properties of an LHRH antagonist (ORF-18260)
8. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer of 3 versus 2 mg
9. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation
10. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)
11. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist
12. Treatment of uterine leiomyomas with luteinizing hormone releasing hormone antagonist Cetrorelix
13. Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix
14. Treatment of patients with advanced prostate cancer with LHRH antagonist Cetrorelix
15. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone
16. High affinity binding and direct antiproliferative effects of LHRH analogues in human endometrial cancer cell lines
17. High affinity binding sites and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines
18. Birth after reimplantation of human embryos
19. Current status of in-vitro fertilization and implantation of human embryos
20. Pregnancies in human by fertilization in vitro and embryo transfer in the controlled ovulatory cycle
21. The program for in-vitro fertilization at Norfolk
22. Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase
23. Clinical aspects with regards to the occurrence of an endogenous luteinizing hormone surge in gonadotropin-induced normal menstrual cycles
24. Ovarian hyperstimulation for in-vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotrophins
25. The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer
26. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation
27. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation
28. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg
29. Ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin
30. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of luteinizing hormone-releasing hormone (LH-RH) antagonist (Cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)
31. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial
32. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles
33. Embryo implantation: The rubicon for GnRH antagonists
34. Addition of GnRH antagonist in cycles of poor responders undergoing IVF
35. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist
36. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: Preliminary report
37. Estrogene-induced human luteolysis
38. An intraovarian site for the luteolytic action of estrogen in the rhesus monkey
39. A pilot study involving minimal ovarian stimulation for in vitro fertilization: Extending the 'follicle-stimulating hormone window' combined with the gonadotropin-releasing hormone antagonist cetrorelix
40. Treatment of leiomyomata uteri with lupreolide acetate depot: A double-blind, placebo-controlled, multicenter study
41. Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata
42. Treatment of uterine fibroids with a slow-release formulation of gonadotrophin releasing hormone antagonist Cetrorelix
43. Responses to the antagonist analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia (BPH) and prostatic cancer
44. The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers
45. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75)
46. Antiproliferative effects of luteinizing hormone releasing hormone agonists on the human prostatic cancer cell line LNCaP
47. Lupron retards proliferation of ovarian epithelial tumor cells, cultured in serum free medium
48. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer
49. The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor
50. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial
51. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75
52. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers
53. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145
54. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines